Psilocybin, a hallucinogen, significantly reduced symptoms of anxiety and depression in 70% of participants with personality disorders. In a study involving 100 individuals, those treated with psilocybin reported a 60% improvement in overall mental health after just one session. Neuroscience insights suggest that psychedelics may promote neural connectivity, enhancing emotional regulation. This promising approach could transform mental health and psychiatry, offering new hope for those struggling with severe psychopathology and highlighting the potential of psychedelics in therapeutic settings.
Two modifications of an HPLC-ED method for measuring psilocin, the active metabolite of psilocybin, in human plasma were developed and compared. One used liquid-liquid extraction (LLE) and the other automated on-line solid-phase extraction (on-line SPE). Both methods had a limit of quantitation of 10 ng/ml psilocin and showed no significant difference in standard deviation (LLE 1.82%, on-line SPE 1.13%) or analytical results. On-line SPE required less manual effort, smaller plasma volumes (400 microl versus 2 ml), and achieved nearly 100% recovery of psilocin (LLE 88%). Both methods were rapid, simple, and reliable, and were successfully used to quantify psilocin in plasma samples from healthy volunteers after oral administration of 0.2 mg psilocybin per kg body mass.